By Emily Field. Law360, New York (March 17, 2016, 11:30 PM ET) -- A Utah
federal judge on Wednesday tossed claims, brought by a ... The case is Cerveny
et al v. Sanofi et al., case number 2:14-cv-00545, in the U.S. District Court for the.
Amgen Inc. v. Sanofi et al. 1:14-cv-01393; Filed: 11/11/2014; Case Updated Daily
; Latest Docket Entry: 12/15/2014; PACER. Create Alert. ×.
Parties, docket activity and news coverage of federal case Amgen Inc. v. Sanofi et
al, case number 1:14-cv-01414, from Delaware Court.
Oct 15, 2011 ... Phase I. Sanofi/ImmunoGen. huB4-SPDB-DM4 .... Jeffrey SC, Torgov MY,
Andreyka JB, Boddington L, Cerveny CG,. Denny WA, et al. ... V, et al. Phase II
radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer ...
... dose rate, the quality of radiation, and the time and extent of bodily exposure (;;
). ... and either have been or are currently being developed for FDA approval (;;,).
..... 2 h after irradiation had lower efficacy than a pre-irradiation injection (i.e., 12
% vs. ..... (sargramostim) is 5–10 μg kg<sup>−1</sup> d<sup>−1</sup> sc or (200–400 μg m<sup>−2</sup> d<sup>−1</sup>) (;)...
Mar 7, 2016 ... SAR408701, Sanofi, 1, 2, Solid, CEACAM5, DM4, SPDB, Yes ..... 15; J.A.
Francisco, C.G. Cerveny, D.L. Meyer, B.J. Mixan, K. Klussman, D.F. ..... D.S.
Siegel, T.M. Zimmerman, S. Jagannath, N.C. Munshi, S. Lonial, V. Roy, et al.
Behrens and Liu (2014) and Panowksi et al. ... Sanofi-Genzyme,
Glycoengineering .... The importance of conjugation site was also described by
Strop et al. ..... Barginear et al., 2012; M.F. Barginear, V. John, D.R. Budman ...
B.A. Mendelsohn, C.G. Cerveny, D.F. Chace, R.L. DeBlanc, R.P. Gearing, T.D.
Bovee, C.B. Siegall, et ...
Apr 26, 2015 ... Vss=volume of distribution at steady state. tmax=time to reach the maximum
concentration. ..... CD19-targeted maytansinoid antibody–drug conjugate
SAR3419 (Sanofi, Paris, .... 9Francisco, JA, Cerveny, CG, Meyer, DL et al.
Jun 20, 2012 ... Abstract/FREE Full Text. ↵. Diehl V,; Franklin J,; Pfreundschuh M,; et al. ...
Francisco JA,; Cerveny CG,; Meyer DL,; et al. (2003) cAC10-vcMMAE ...
Dec 4, 2010 ... The response rates and time to progression were similar (49% vs 43% and 7
months vs 10 months in arm A .... Calistoga, Johnson & Johnson, EMD Serono,
sanofi-aventis, Millenium, Biotest, Cephalon, Pharmion, Eisai, ... Hagenbeek A,;
Fayad L,; Delwail V,; et al. .... Baum PR,; Cerveny C,; Gordon B,; et al.